Mustang Bio Inc (NASDAQ:MBIO) announced that final data from the follicular lymphoma cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response (ORR) and complete response (CR) rates and CAR T persistence.
MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
20 patients with relapsed FL with confirmed CD20 expression participated in the study. ORR was 95% (19/20), and the CR rate was 80% (16/20).
Patients who received higher dose levels had an ORR of 100% and a CR rate of 91%. Ten patients are in remission over one year, seven of whom are over two years.
One patient, previously treated with a CD19-targeted CAR T-cell therapy, achieved a CR and remains in remission after 18 months.
From a safety profile perspective, all cytokine release syndrome events were grade 1 or grade 2, with no grade ≥ 3 CRS events. There was no occurrence of immune effector cell-associated neurotoxicity syndrome of any grade.
Price Action: MBIO shares are up 9.44% at $8.00 on the last check Friday.
